Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Prothena (PRTA – Research Report) today and set a price target of $94.00. The company’s shares closed yesterday at $22.00.
Rahimi covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Soleno Therapeutics, and Savara. According to TipRanks, Rahimi has an average return of 4.5% and a 36.85% success rate on recommended stocks.
Currently, the analyst consensus on Prothena is a Strong Buy with an average price target of $74.83, which is a 240.14% upside from current levels. In a report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $83.00 price target.
The company has a one-year high of $77.13 and a one-year low of $19.65. Currently, Prothena has an average volume of 596.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Prothena (PRTA) Company Description:
Prothena Corp. Plc is a late-stage clinical biotechnology company, which research, development and commercialization of therapies in the neuroscience and orphan categories. Its antibody-based product candidates target a potential indications including amyloidosis and Parkinson’s disease. The company was founded in December 1969 and is headquartered in Dublin, Ireland.
